A Biotechnology Crossroads
By Becca Muir,
Science for the People
| 02. 01. 2021
Before Tina Stevens and Stuart Newman wrote Biotech Juggernaut, Newman helped Stevens fight legal action from an unexpectedly powerful adversary. Two scientists and the financer-author of Proposition 71, a 2004 California state initiative to fund stem cell medicine and promising imminent cures, wanted to prevent Stevens expressing her “false and misleading” views about the bill. Advocates said Proposition 71 would lead to miracle treatments for serious, debilitating illnesses such as Alzheimer’s, multiple sclerosis and heart disease. Using DNA from a patient and an egg donated by a healthy woman, researchers would produce embryonic stem cells that could then specialise and replace virtually any cell in the patient’s body.
But, Stevens, a bioethicist and historian, felt uneasy about the scientific and ethical claims of the proposition. She was part of a progressive wing of activists who were concerned about the serious risks posed to women who donated eggs for this research, as well as the troubling ethical implications of some of the techniques used. The type of stem cell research proposed in the proposition constituted a form of human cloning – somatic...
Related Articles
By Yelena Biberman and Jonathan D. Moreno, Bioethics Forum | 04.16.2024
A quiet biological revolution in warfare is underway. The genome is emerging as a new domain of conflict. The level of destruction that only nuclear weapons could previously achieve is fast becoming as accessible as a cyberattack.
Now for the...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...